Molecular Assessment for Gastro-Esophageal Cancer (NCT06346054) | Clinical Trial Compass
RecruitingNot Applicable
Molecular Assessment for Gastro-Esophageal Cancer
Belgium1,000 participantsStarted 2024-08-01
Plain-language summary
The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.
The main questions this study aims to answer:
Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.
Participants will provide a breath and blood sample during their routine standard of care visits.
Who can participate
Age range18 Years – 100 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any breath or blood analysis
✓. \>18 years old
✓. Barrett's esophagus or treatment naïve gastro-esophageal cancer stage I to IV
✓. Voluntary healthy controls
Exclusion criteria
✕. \<18 years old
✕. Patient has history of:
✕. Active other cancer than gastro-esophageal cancer
✕. Prior cancer treated \<3 years ago
✕. Hepatic dysfunction/liver failure (MELT \>7)
✕. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the study plan.
✕
What they're measuring
1
Identification of the concentrations of oncometabolites